Study Type
Interventional - Drug
ongoing
HD PCI is a multicenter, international, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing percutaneous coronary intervention (PCI) for non-ST elevation acute coronary syndrome (NSTEACS) or stable angina.
The objectives are:
- To determine if higher dose heparin reduces the composite of death, myocardial infarction (MI) or target vessel revascularization (TVR) compared to lower dose heparin in patients undergoing PCI for NSTEACS or stable angina
- To determine if lower dose heparin reduces serious bleeding, as measured by the need for blood transfusion after PCI
- To determine if higher dose heparin improves the net benefit outcome of death, MI, TVR or need for blood transfusion.
Study Design
Randomized registry-based cluster crossover
NO. of Countries
1
NO. of Sites
20 target
NO. of Participants
15366 target
Study Period
2020 - 2022
Sponsor
PHRI
Sanjit Jolly
Scientist
Sanjit Jolly
Scientist
Sanjit Jolly is an interventional cardiologist at Hamilton Health Sciences and associate professor at McMaster University. He has formal training in clinical trials with a M.Sc. in Health Research Methodology from McMaster. He was the principal investigator of the RIVAL trial, a randomized trial of 7021 patients comparing radial and femoral access for coronary intervention. He is also the principal investigator trial of the ongoing TOTAL trial, an international randomized trial (N=10,700) of thrombectomy during primary PCI.
Jessica Tyrwhitt
Program Manager
Jessica Tyrwhitt
Program Manager
Jessica Tyrwhitt has more than 10 years’ experience in coordinating and managing large, international clinical trials. She oversees interventional trials, registries, and observational research studies looking at primary and secondary prevention of cardiovascular disease in a variety of therapeutic areas, including cardiology, thrombosis, nephrology, cardio-oncology and diabetes.
She holds an Honours Bachelor of Science Degree & Business from the University of Waterloo.
